Combinational Immunotherapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Combinational Immunotherapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT07063875

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the c…

Australia8 participantsStarted 2025-06-01

Treatment: Aldesleukin

All recent trials (4 shown)

CompletedPhase 1/2

NCT01326871

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisp…

United States68 participantsStarted 2011-09-06

Treatment: Cisplatin, Gemcitabine

UnknownPhase 1

NCT05031949

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advan…

China20 participantsStarted 2021-10-30

Treatment: hyperbaric oxygen therapy plus Camrelizumab

Combinational Immunotherapy

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

All recent trials (4 shown)

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

All recent trials (4 shown)

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors